Business

First Solar reported incredible third quarter results after the markets closed Tuesday, investors cheered on these results.
One aspect of life that has managed to survive, and even thrive, during the pandemic has been outdoor activities and entertainment. Golf fits within this theme perfectly. After all, you can play...
Many investors use an alternative valuation approach in their investments. Rather than looking at a book value in financial stocks, an alternative measurement that is using a “sum of the...
Short interest in solar and alt energy stocks was mixed in the two-week reporting period ended October 15. Short sellers made sharp changes in several of the stocks.
Catabasis Pharmaceuticalswas absolutely devastated on Tuesday after the company announced top-line results from its late-stage study in muscular dystrophy.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Short interest moves in oil and gas stocks were mixed in the two-week reporting period that ended October 15.
Motorcycle maker Harley-Davidson rode roughshod over earnings estimates when it reported third-quarter results Tuesday morning.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Short interest in electric vehicle makers was evenly mixed in the two-week reporting period that ended October 15. But a couple of truck makers got some bad news Monday.
Having a fleet of fully electric cars on the road is already becoming to be considered to be within the realm of possibilities in the years and decades ahead. But what about all of those heavy trucks...
Gun sales in the first nine months of this year have already set an annual record, surpassing the record set in all of last year.
BioSig Technologies was absolutely crushed on Monday after the company announced that it would be halting its midstage coronavirus study.
A new report projects sales of hemp-derived CBD products could rise to around $1.8 billion in 2020, on their way to a rise of more than three times by 2025.
Clinical-stage biopharmaceutical company Atea Pharma intends to price 11 million shares for and intial public offering valued up to more than $303 million.